| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/17/2008 | WO2007073177A3 Composition comprising polyunsaturated fatty acids for improving membrane composition |
| 07/17/2008 | WO2007062483A8 Increasing pregnancy rates |
| 07/17/2008 | WO2007053844A8 Compositions and methods for treating inflammatory disorders |
| 07/17/2008 | WO2006128045A3 Use of polyamines with antibiotics |
| 07/17/2008 | WO2006112872A3 Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
| 07/17/2008 | WO2006002038A3 Immunostimulatory oligonucleotide multimers |
| 07/17/2008 | US20080172751 Agent Comprising Fgf2 as an Effective Ingredient For Treatment or Prevention of Asthma and Chronic Obstructive Pulmonary Disease |
| 07/17/2008 | US20080172057 Spine distraction implant and method |
| 07/17/2008 | US20080172014 Extended therapeutic effect ocular implant treatments |
| 07/17/2008 | US20080171882 [(4S)-4-Methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride and [(4R)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride; chemical intermediates for enzyme inhibitors |
| 07/17/2008 | US20080171880 N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible |
| 07/17/2008 | US20080171874 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines |
| 07/17/2008 | US20080171862 Double stranded RNA packaged in liposome for use therapeutic tool in treatment of cell proliferative and viral disorders; Antisense oligonucleotide for use in prevention and treatment of viral and tumor disorders; gene expression inhibition; RNA interference |
| 07/17/2008 | US20080171861 Method and medicament for inhibiting the expression of a given gene |
| 07/17/2008 | US20080171795 Novel Inter and Intra Multilamellar Vesicular Composition |
| 07/17/2008 | US20080171794 Humectant composition |
| 07/17/2008 | US20080171793 poly(imino-keto-methylene/amine) derivatives as a bioactive part in conjugates; diarrhea caused by pathogens: Vibrio cholerae, Clostridium difficile, Escherichia coli, Shigella, Salmonella, rotavirus; or enterotoxins: cholera toxin, E. coli toxin, Salmonella toxin |
| 07/17/2008 | US20080171792 Administering aqueous sodium 4-phenylbutyrate to treat spinal muscular atrophy, central nervous system cancer, myelodysplastic syndrome, acute leukemia, glioblastoma multiforme, amyotrophic lateral sclerosis and colon cancer; cherry flavored liquid for children |
| 07/17/2008 | US20080171791 Compositions and Method for Losing Weight |
| 07/17/2008 | US20080171790 Fatty acids-systemic lipid solubilizers conjugates |
| 07/17/2008 | US20080171789 Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| 07/17/2008 | US20080171788 N-(diaminomethylene)-9H-fluorene-2-carboxamide derivatives; dual antagonist for 5-HT2B and 5-HT7 receptors having selective binding affinities for 5-HT2B and 5-HT7 receptors; side effect reduction, nontoxic |
| 07/17/2008 | US20080171787 Colchicine neoglycosides and methods for their synthesis and use |
| 07/17/2008 | US20080171786 Substituted [(Phenylethanoyl)Amino]Benzamides |
| 07/17/2008 | US20080171785 Dosing Regimens For Ion Channel Modulating Compounds |
| 07/17/2008 | US20080171784 Stabilization of the pharmaceutical active solid substance atorvastatin (Lipitor) alone or in a mixture with other solid substances embedded in a surrounding gaseous mixturewhere a partial pressure of oxygen of at < 2 kPa is maintained; amorphous; blister-pack using an oxygen self-activating absorber |
| 07/17/2008 | US20080171783 Compositions and methods for treating hyperproliferative disease |
| 07/17/2008 | US20080171782 2-[5-(3-Methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil) and derivatives; anticarcinogenic agents; leukemia; antiinflammatory agents; multiple sclerosis, antiarthritic agents; rheumatic diseases;osteoporosis, stroke, asthma; glaucoma; screening; catalyzed CaaX protein methylation |
| 07/17/2008 | US20080171781 Administering an extract of safflower seeds, p-coumaroyl, feruloyl or caffoyl serotonin, to suppress an increase of the pulse wave velocity and Augmentation Index, and decrease the systolic and mean blood pressure and pulse pressure; vascular ageing resistance; atherosclerosis; oral dosage; food additive |
| 07/17/2008 | US20080171780 Process for Crystallization of Ramipril and Preparation of a Hydrated Form Thereof |
| 07/17/2008 | US20080171779 Use of 5-ht6 antagonists to prevent relapse into addiction |
| 07/17/2008 | US20080171778 N3 alkylated benzimidazole derivatives as mek inhibitors |
| 07/17/2008 | US20080171777 Biaryl substituted triazoles as sodium channel blockers |
| 07/17/2008 | US20080171776 6-oxazol-4-ylmetholmethoxy-alko-alkoxymethyl substituted benzoic acid derivatives forming peroxisome proliferator - activated receptor (ppar) ligands, process for their preparation and methods of use thereof |
| 07/17/2008 | US20080171775 Ramipril-amlodipine salt |
| 07/17/2008 | US20080171774 e.g. 2-chloro-N-(3',4'-dichlorobiphenyl-2-yl)nicotinamide; controlling phytopathogenic harmful fungi and plant diseases: Alternaria, Aphanomyces, Bipolaris, Drechslera, Bremia lactucae, Drechslera, Erysiphe cichoracearum, Sphaerotheca fuliginea, Fusarium and Verticillium species |
| 07/17/2008 | US20080171773 A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc |
| 07/17/2008 | US20080171772 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| 07/17/2008 | US20080171771 New Compounds 391 |
| 07/17/2008 | US20080171770 e.g. 2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}aceta mide; vanilloid receptor 1 (VR1 or TRPV1) antagonist; antiinflammatory agent; neuropathic pain; arthritis, ischaemia, fibromyalgia, asthma, cough, inflammatory bowel disease, obesity |
| 07/17/2008 | US20080171769 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| 07/17/2008 | US20080171768 Pharmaceutical Composition Containing An Anti Parasitic Agent And Active Ingredient Selected From Carveol, Thymol, Eugenol, Borneol, Carvacrol, Alpha-Ionone, Or Beta-Ionone |
| 07/17/2008 | US20080171766 Administering pleuromutilin derivative for treatment/prophylaxis of infection caused by antimicrobial resistant bacteria |
| 07/17/2008 | US20080171765 e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma |
| 07/17/2008 | US20080171764 Determining the efficiency of treating atherosclerosis by inhibiting the infiltration and/or accumulation of inflammatory cells proximate a site of altered vascular tissue by using an agent binding FK binding protein and inhibiting mTOR (mammalian target of rapamycin); sirolimus and analogs |
| 07/17/2008 | US20080171763 Compounds and methods for treatment and prevention of diseases |
| 07/17/2008 | US20080171762 Treatment of pain with naloxone |
| 07/17/2008 | US20080171761 Substituted spirochromanone derivatives |
| 07/17/2008 | US20080171760 e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder |
| 07/17/2008 | US20080171759 e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder |
| 07/17/2008 | US20080171758 Compounds and methods for the treatment of cancer |
| 07/17/2008 | US20080171757 Methods to identify inhibitors of cell sickling |
| 07/17/2008 | US20080171756 e.g. N-{[4-hydroxy-6-oxo-2-phenyl-1-(phenylmethyl)-1,6-dihydro-5-pyrimidinyl]carbonyl}glycine; anemia caused by increasing the production of erythropoietin (Epo), ischemia, stroke, and cytoprotection |
| 07/17/2008 | US20080171755 4-(4-Benzo[1,3]dioxol-5-yl-1H-pyrazol-3-yl)-2-methylpyrimidine; affinity for activin receptor-like kinases 4/5; potent antagonists of these Transforming Growth Factor beta family type receptors; fibrosis; anticarcinogenic and -metastasis agents; demelination; expression inhibited by reducing signal path |
| 07/17/2008 | US20080171754 Certain pyrazoline derivatives with kinase inhibitory activity |
| 07/17/2008 | US20080171753 Carbamoyl-Substituted Spiro Derivative |
| 07/17/2008 | US20080171752 5-HT1A Receptor Subtype Agonist |
| 07/17/2008 | US20080171751 e.g., 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-(1-methylcyclopropyl)-pyrimidine hydrochloride; central nervous system disorders; schizophrenia; antidepressant, anxiolytic agent, cognition activator; Parkinson's and Alzheimer's diseases |
| 07/17/2008 | US20080171750 Modulation Of Neurogenesis With Use of Modafinil |
| 07/17/2008 | US20080171749 e.g. 2-(4-Cyclohexyl-piperazin-1-yl)-2-(4-methoxy-phenyl)-acetonitril; antiinflammatory, antiallerge agent,autoimmune diseases; asthma, rheumatoid arthritis, atherosclerosis or allergic diseases wherein the activity of a CCR3 receptor is involved |
| 07/17/2008 | US20080171748 {(2S,4R,5R)-4-(4-Methoxy-phenyl)-5-[4-(3-methoxy-propyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethoxy]-piperidin-2-yl}-methanol; renin enzyme inhibitor; hypertensive agent; heart/kidney failure; glaucoma cardiac infarction; restenosis; stroke; reduces forming of angiotensin I, therefore angiotensin II als |
| 07/17/2008 | US20080171747 Preparing 1-methyl,2-oxo,3-ethyl,4-cyclopentyl,6-chloro-1,2,3,4-tetrahydropteridine by reacting ethyl 2-N-cyclopentylaminobutyrate hydrochloride with 2,4-dichloro-5-aminopyrimidine; reducing, cyclizing and methylating by electrolytic substitution; antiproliferative, -carcinogenic and -tumor agents |
| 07/17/2008 | US20080171746 Method for Preventing Cardiovascular Diseases |
| 07/17/2008 | US20080171745 Methods relating to the treatment of fibrosis |
| 07/17/2008 | US20080171744 Compounds and method for treatment of cancer |
| 07/17/2008 | US20080171743 Transcutaneous immunostimulation |
| 07/17/2008 | US20080171742 e.g. 6-methyl-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(pyrid-2-ylamino)pyrimidine; insulin-like growth factor 1 receptor (somatomedin) antagonist; antiproliferative, antitumor, anticarcinogenic agent; |
| 07/17/2008 | US20080171741 e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia |
| 07/17/2008 | US20080171740 5,6,7,8-tetrahydro-8-quinolinamines as chemokine receptor CXCR4 antagonists such as N-(Imidazo[1,2-a]pyridin-2-ylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-butanediamine; HIV infection, rheumatoid arthritis; antiinflammatory, anticarcinogenic agent |
| 07/17/2008 | US20080171739 e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency |
| 07/17/2008 | US20080171738 Administering a methylol-transferring antiproliferative agent taurolidine, taurultam or a mixture in dosing cycles of an administration phase of daily dose for 1-8days followed by a non-adminstration (rest) phase of 1-14 days; infusion; before or after suregical removal; antitumor, -carcinogenic agents |
| 07/17/2008 | US20080171737 Cyclic sulfonamide derivatives and methods of their use |
| 07/17/2008 | US20080171736 Administering a synergistic combination of a gonadotropin releasing hormone analog, leuprolide acetate, and either or both of an acetylcholinesterase inhibitor donepezil, rivastigimine, galantamine, and/or tacrine and an N-methyl-D-aspartate receptor antagon , memantine; sex steroid antagonists |
| 07/17/2008 | US20080171735 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| 07/17/2008 | US20080171733 Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine |
| 07/17/2008 | US20080171732 e.g. ethyl6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-2-methoxynicotinate; reversible and selective purinergic receptor antagonist; anticoagulant; cardiovascular diseases; platelet aggregation, thrombotic occlusion, myocardial infarction and unstable angina |
| 07/17/2008 | US20080171731 Prevention of ovarian cancer by administration of a vitamin d compound |
| 07/17/2008 | US20080171730 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes and vascular and renal disorders |
| 07/17/2008 | US20080171729 For an antiinflammatory agent, antiacne agent, antiproliferative agent, antiphototoxic agent, anti-hair loss agent, analgesic, antiaging agent, antiperspirant, antipruritic, astringent, or microbiocide; calcineurin inhibitors |
| 07/17/2008 | US20080171728 Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone |
| 07/17/2008 | US20080171727 Administering a photosensitive, non-antibiotic tetracycline, preferably chosen from CMT-1 through CMT-10, without administering a bisphosphonate compound; side effect reduction |
| 07/17/2008 | US20080171726 oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in biological materials (cells, tissues); organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer |
| 07/17/2008 | US20080171725 Oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in cells or tissues; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer |
| 07/17/2008 | US20080171724 Phosphonate Derivatives of Mycophenolic Acid |
| 07/17/2008 | US20080171723 Boronic Acid Aryl Analogs |
| 07/17/2008 | US20080171722 Low molecular weight heparins that are substantially pure and have homogeneous structural configurations, confirmations, and stereomeric compositions; buffered saline solutions; substituted 6,8-dioxabicyclo(3.2.1)octane or furo[2,3-D]-1,3-dioxole synthetic precursors |
| 07/17/2008 | US20080171721 Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment |
| 07/17/2008 | US20080171720 Nutritional Supplement For Hiv Patients |
| 07/17/2008 | US20080171719 RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
| 07/17/2008 | US20080171718 The atisense agent, an oblimersen compound, is administered twice weekly, the tyrosine kinase inhibitor is administered five times weekly, and the chemo agent once weekly; synergistic |
| 07/17/2008 | US20080171717 Double-Stranded Synthetic Oligonucleotides Useful For Inducing Apoptosis of Osteoclasts For the Treatment of Osteopenic Pathologies |
| 07/17/2008 | US20080171716 Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
| 07/17/2008 | US20080171715 Methods and compositions involving mirna and mirna inhibitor molecules |
| 07/17/2008 | US20080171714 Substances for preventing and treating autoimmune diseases |
| 07/17/2008 | US20080171713 Substances for preventing and treating autoimmune diseases |
| 07/17/2008 | US20080171711 One mRNA contains a domain coding for a tumor antigen and one mRNA contains a domain coding for an immunogenic protein; genetic vaccines; gene therapy; improved stability |
| 07/17/2008 | US20080171710 Reducing oxidation in activated neural progenitor cells, islets of Langerhan or oligodendrocytes by contacting with an interupting agent; screening for pro-oxidation toxicants; cancer treatments; testing oxidation levels in patients at risk for autism, Alzheimer's Disease and environmental toxin exposure |
| 07/17/2008 | US20080171709 Pharmaceutical Composition Comprising An Antiviral Agent, An Antitumoral Agent Or An Antiparasitic Agent, And An Active Agent Selected Among Carveol, Thymol, Eugenol, Borneol,And Carvacrol |
| 07/17/2008 | US20080171708 luteolin derivatives, e.g. 7-(6''- beta -D-apiofuranosyl)- beta -D-glucopyranoside; plant extract from Capsicum annuum (sweet bell pepper); no burning sensations and erythema; with other analgesics, antiinflammatories, NSAIDs, acetaminophen, ibuprofen, and COX-2 inhibitors; inflammation bioassay |
| 07/17/2008 | US20080171707 Flavonoids, glycosylated flavonoids, free form or glycosylated quercetin; nutraceuticals |